<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03309761</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2016-02/PC-01</org_study_id>
    <nct_id>NCT03309761</nct_id>
  </id_info>
  <brief_title>Description of an Immune Activation Profile Linked to Insulin Resistance in Subjects Aged 55-69</brief_title>
  <acronym>METACTIV</acronym>
  <official_title>Description of an Immune Activation Profile Linked to Insulin Resistance in Subjects Aged 55-69</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to describe an immune activation profile of people at risk of insulin
      resistance based on a wide range of markers which will allow easy identification of patients
      at risk.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cluster of Differentiation 4 (CD4+) T cell subpopulations</measure>
    <time_frame>Day 0</time_frame>
    <description>immunosenescence; number/mm3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cluster of Differentiation 8 (CD8+) T cell subpopulations</measure>
    <time_frame>Day 0</time_frame>
    <description>immunosenescence; number/mm3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>B cell subpopulations</measure>
    <time_frame>Day 0</time_frame>
    <description>flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Natural killer (NK) cell subpopulations</measure>
    <time_frame>Day 0</time_frame>
    <description>immunosenescence; number/mm3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sCD14 level</measure>
    <time_frame>Day 0</time_frame>
    <description>ng/ml, enzyme-linked immunosorbent assays (ELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>16 ribosomal ribonucleic acid (rRNA) levels</measure>
    <time_frame>Day 0</time_frame>
    <description>polymerase chain reaction (PCR); copies/µl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>lipopolysaccharide (LPS)-binding protein level</measure>
    <time_frame>Day 0</time_frame>
    <description>ELISA; µg/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intestinal Fatty Acid Binding Protein level</measure>
    <time_frame>Day 0</time_frame>
    <description>ELISA; pg/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>Day 0</time_frame>
    <description>mM/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High Density Lipoprotein</measure>
    <time_frame>Day 0</time_frame>
    <description>mM/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low Density Lipoprotein</measure>
    <time_frame>Day 0</time_frame>
    <description>mM/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fasting glycemia</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fasting insulinemia</measure>
    <time_frame>Day 0</time_frame>
    <description>mIU/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>γ-glutamyl transpeptidase level</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>glutamic pyruvic transaminase</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>hip circumference</measure>
    <time_frame>Day 0</time_frame>
    <description>cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>waist circumference</measure>
    <time_frame>Day 0</time_frame>
    <description>cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>minimal arterial tension</measure>
    <time_frame>Day 0</time_frame>
    <description>mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>maximal arterial tension</measure>
    <time_frame>Day 0</time_frame>
    <description>mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cluster of Differentiation 163 (CD163) level</measure>
    <time_frame>Day 0</time_frame>
    <description>ng/ml, enzyme-linked immunosorbent assays (ELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>soluble tumor necrosis factor-alpha receptor I (sTNFRI) level</measure>
    <time_frame>Day 0</time_frame>
    <description>ng/ml, enzyme-linked immunosorbent assays (ELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>soluble endothelial protein C Receptro (sEPCR) level</measure>
    <time_frame>Day 0</time_frame>
    <description>ng/ml, enzyme-linked immunosorbent assays (ELISA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tissue plasminogen activator (tPa) level</measure>
    <time_frame>Day 0</time_frame>
    <description>ng/ml, enzyme-linked immunosorbent assays (ELISA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of insulin and metabolic syndrome</measure>
    <time_frame>Day 0</time_frame>
    <description>% subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Link between immune activation profile and other features of metabolic syndrome</measure>
    <time_frame>Day 0</time_frame>
    <description>logistic regression of individual markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune activation linked to the profile</measure>
    <time_frame>Day 0</time_frame>
    <description>logistic regression</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Patients aged 55-60</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>6ml blood sample taken</description>
    <arm_group_label>Patients aged 55-60</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Volunteers aged between 55-69
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has been informed of the study, its objectives, constraints and the
             patient rights

          -  The patient must have given their free and informed consent and signed the consent
             form

          -  The patient is aged 55-69

          -  The patient has been recruited at the Centre of health exams of the social security in
             Nimes as part of the CONSTANCES cohort

        Exclusion Criteria:

          -  The subject is participating in an interventional category 1 study other than
             CONSTANCES

          -  The patient has participated in another category 1 interventional study in the last 3
             months

          -  The patient is in a period of exclusion determined by a previous study

          -  The patient is under safeguard of justice or state guardianship

          -  The subject refuses to sign the consent

          -  The subject does not understand the information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre Corbeau</last_name>
    <phone>+33 (0)4 66 68 31 49</phone>
    <email>pierre.corbeau@igh.cnrs.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Corbeau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Philippe Lavigne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Sabatier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'examen de santé de la Sécurité Sociale de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Maggia</last_name>
      <phone>04 30 67 94 70</phone>
      <email>elisabeth.maggia@cpam-nimes.cnamts.fr</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Maggia</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patricia Le Merre</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2017</study_first_submitted>
  <study_first_submitted_qc>October 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

